## Abstract Intravenous immunoglobulin (IGIV) therapy is generally considered to be a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP). The usual initial treatment dose is 1β2 g/kg body weight, which results in an extended infusion time, significantly impacting patients' d
Immune thrombocytopenic purpura and intravenous immunoglobulin
β Scribed by Paul Imbach
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 407 KB
- Volume
- 68
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Multiple factors, including efficacy, toxicity and cost, may influence the decision to treat immune thrombocytopenic purpura (ITP) with intravenous immune globulin (IVIG) or intravenous Rho (D) immune globulin (IV RhIG). We conducted a survey of 50 hospitals in 31 states to determine the costs for t
To the editor: A 60-year-old male was evaluated for episodes of gingival bleed. Past medical history was significant for hypertension currently treated with clonidine and aliskiren and early stage prostate cancer. Social and family histories were noncontributory. Review of systems was negative excep
## Abstract Immune thrombocytopenic purpura is rarely seen in Hodgkin disease and the presence of plateletβassociated antibody has not been previously reported in these patients. A patient with Hodgkin disease is described who developed a destructive thrombocytopenia demonstrated by shortened plate